Psychiatry and clinical neurosciences
December 1, 2024
Yohei Ohtani, Hideaki Tani, Kie Nomoto-Takahashi et al.
13 citations
In a double-blind randomized placebo-controlled trial with 34 Japanese patients suffering from treatment-resistant depression, intravenous ketamine (0.5 mg/kg) given twice a week for two weeks did not show a statistically significant advantage over placebo in reducing depression scores when all participants were analyzed together. However, among those who completed the full treatment protocol, ketamine led to a significantly greater reduction in depressive symptoms than placebo. Higher baseline depression severity and body mass index were linked to greater symptom improvement with ketamine. Adverse events were more common with ketamine but no serious events occurred. These results suggest ketamine may be effective for treatment-resistant depression across diverse ethnic groups.
Psychiatry and clinical neurosciences
April 1, 2024
Ting Xue, Jialing Sheng, Hui Gao et al.
5 citations
An 8-month daily guided intensive meditation-based intervention (iMI) added to a general rehabilitation program reduced persistent hallucinations and delusions and improved health-related quality of life in male inpatients with treatment-refractory schizophrenia. In a randomized trial of 64 participants, those receiving iMI showed significantly greater reductions in Positive and Negative Syndrome Scale total scores, positive symptoms, and hallucination/delusion items at both 3 and 8 months compared with rehabilitation alone. Treatment response rates (at least 25% reduction) for these measures were higher in the iMI group at 8 months. The iMI group also reported better physical activity and mindfulness skills. Longer iMI duration produced stronger benefits.
Psychiatry and clinical neurosciences
July 15, 2025
Hitoshi Sakurai, Daiki Setoyama, Takahiro A Kato et al.
1 citation
In an open-label study of 30 patients with treatment-resistant depression, four intravenous ketamine infusions (0.5 mg/kg) over two weeks rapidly reduced depression severity: the average Montgomery-Åsberg Depression Rating Scale score fell from 30.6 to 20.3 after the fourth infusion, and 26.7% of participants achieved remission. However, only 13.3% remained in remission at 12 months. Early changes in the metabolite 3-hydroxybutyrate predicted the degree of improvement both after the fourth infusion and at 12 months, suggesting it could serve as a biomarker for treatment response. The findings point toward more individualized use of ketamine infusions.
Psychiatry and clinical neurosciences
May 30, 2026
Nathalia Novaretti, Rebeca Mendes P Pessoa, Jaime Eduardo Cecílio Hallak et al.
Oral ketamine shows a favorable short-term safety profile across a range of uses, including depression, chronic pain, and pediatric sedation, based on a systematic review of 18 randomized controlled trials involving adults, children, and healthy volunteers. Adverse effects were predominantly mild and transient; in depression studies (427 participants), effects were mild, and pediatric premedication trials (239 participants) reported transient neurological effects without significant safety concerns. Pain and experimental studies (372 participants) showed mostly mild adverse events, with dissociative symptoms at higher doses. Dizziness, sedation, and dissociation were more common with ketamine, while serious adverse events were rare. However, the certainty of evidence is low, and long-term safety remains uncertain.